IV Iron Sucrose Evaluated for Iron Deficiency Anemia in Pediatric IBD

The chart review included 72 pediatric IBD patients who received infusions of iron sucrose for the treatment of IDA
The chart review included 72 pediatric IBD patients who received infusions of iron sucrose for the treatment of IDA

For pediatric patients with inflammatory bowel disease (IBD), treating iron deficiency anemia (IDA) with intravenous iron sucrose is both safe and possibly effective, according to findings from a recent retrospective chart review.

The chart review included 72 pediatric IBD patients who received infusions of iron sucrose for the treatment of IDA between 2011 and 2015 at a single tertiary care center. Of the 72 patients included, 53 had Crohn's disease, 11 had ulcerative colitis, and 8 had an unclassified type of IBD, and a total of 43 patients qualified for and were included in the efficacy analysis. 

Related Articles

The study authors reported, “There was a significant increase in hemoglobin over the treatment course, with mean (±SD) hemoglobin increasing from 9.6 ± 1.2 g/dL at baseline to 12.1 ± 1.3 g/dL after iron sucrose treatment (P<0.001).” Results of the review also found that 18 adverse events occurred in a total of 13 patients (18.1% of patients; 6.6% of infusions), however, none of these adverse events required hospitalization, were life-threatening, or were considered anaphylactic in nature.

Based on this chart review, iron sucrose administered intravenously is a safe and possibly effective option for the treatment of IDA in pediatric patients with IBD.

For more information visit Ovid.com.